| ²é¿´: 376 | »Ø¸´: 3 | |||
| µ±Ç°Ö»ÏÔʾÂú×ãÖ¸¶¨Ìõ¼þµÄ»ØÌû£¬µã»÷ÕâÀï²é¿´±¾»°ÌâµÄËùÓлØÌû | |||
wr12580½ð³æ (ÖøÃûдÊÖ)
|
[ÇóÖú]
Âé·³·ÒëÕªÒª²¢¸øÒ»Ð©½âÊÍ
|
||
|
ÕªÒª¼û£º http://onlinelibrary.wiley.com/d ... 7F49F44D92D2.d04t01 CYP3AºÍCYP2C9µÄÁÙ´²ÒâÒ壬ΪºÎÒªÒÔÕâÁ½¸öøΪÑо¿¶ÔÏó¡£ |
» ²ÂÄãϲ»¶
304Çóµ÷¼Á
ÒѾÓÐ6È˻ظ´
²ÄÁϹ¤³Ìר˶µ÷¼Á
ÒѾÓÐ6È˻ظ´
Ò»Ö¾Ô¸Ìì´ó²ÄÁÏÓ뻯¹¤£¨085600£©×Ü·Ö338
ÒѾÓÐ4È˻ظ´
085700×ÊÔ´Óë»·¾³308Çóµ÷¼Á
ÒѾÓÐ3È˻ظ´
Çó²ÄÁϵ÷¼Á
ÒѾÓÐ8È˻ظ´
294Çóµ÷¼Á²ÄÁÏÓ뻯¹¤×¨Ë¶
ÒѾÓÐ5È˻ظ´
Ò»Ö¾Ô¸»ªÖпƼ¼´óѧ£¬080502£¬354·ÖÇóµ÷¼Á
ÒѾÓÐ4È˻ظ´
Ò»Ö¾Ô¸¼ªÁÖ´óѧ²ÄÁÏѧ˶321Çóµ÷¼Á
ÒѾÓÐ6È˻ظ´
085410È˹¤ÖÇÄÜר˶317Çóµ÷¼Á£¨0854¶¼¿ÉÒÔ£©
ÒѾÓÐ3È˻ظ´
330Çóµ÷¼Á
ÒѾÓÐ3È˻ظ´
» ±¾Ö÷ÌâÏà¹Ø¼ÛÖµÌùÍÆ¼ö£¬¶ÔÄúͬÑùÓаïÖú:
Âé·³°ïæ·ÒëÏÂ
ÒѾÓÐ1È˻ظ´
Âé·³°ïÖú·ÒëÏÂÕâ5¾ä»°£¬Ð»Ð»¸÷λ£¡£¨Ã¿¾ä»°10¸ö½ð±Ò£¬×îºÃÁ¬¹á£©
ÒѾÓÐ9È˻ظ´
Ó¢Ò뺺 Âé·³°ï·ÒëÏÂ
ÒѾÓÐ1È˻ظ´
Âé·³°ïæ·Òë¹þÏÂÃæÕâ¾ä»°°¡£¬°ÑËü·ÒëΪӢÓлл£¡
ÒѾÓÐ6È˻ظ´
Âé·³·ÒëÒ»ÏÂÕªÒª°¡
ÒѾÓÐ1È˻ظ´
·ÒëÂÛÎÄ£¬Óöµ½µãÂé·³£¡£¡
ÒѾÓÐ1È˻ظ´
¼±Òë½âÊÍ˵Ã÷ÐÔµÄ
ÒѾÓÐ1È˻ظ´
Âé·³°ïæ·ÒëÏÂÃæÕâ¶ÎÎÄ×Ö
ÒѾÓÐ3È˻ظ´
ÇóÖú£ºÂé·³°ï·ÒëÏÂÏÂÃæÕâ¾ä»°£¬Ð»Ð»~~
ÒѾÓÐ1È˻ظ´
Âé·³´ó¼Ò°ïæ·ÒëÒ»ÏÂ,¼±Ó÷dz£¸Ðл
ÒѾÓÐ1È˻ظ´
Âé·³ÄÄλ´óÏÀ¸ø·ÒëÒ»ÏÂÁ½¸ö¾ä×Ó
ÒѾÓÐ5È˻ظ´
Õâ¶ÎÓ¢ÎÄÂé·³·ÒëÏ£¬Ð»Ð»
ÒѾÓÐ4È˻ظ´
¡¾ÇóÖúÕªÒª·Òë¡¿ÕªÒªÒÑ·Ò룬Âé·³¸ã»úе·½ÃæµÄ³æÓѰïæָÕýÒ»ÏÂ
ÒѾÓÐ3È˻ظ´
Âé·³Ó¢Óï¸ßÊÖ°ïæ·ÒëÏ£¬ºñÉÍ£¡
ÒѾÓÐ1È˻ظ´
¶à¸öÓ¢ÎÄ·ÒëµÄÎÊÌ⣬ºÇºÇ£¬Âé·³¸÷λ³æÓÑÁË
ÒѾÓÐ4È˻ظ´
Âé·³°ïÖú·ÒëÏ£¬²»ÊÇ×öʵÑéµÄ²»Ì«¶®£¡
ÒѾÓÐ4È˻ظ´
ÇóÓ¢ÎĽâÊÍ
ÒѾÓÐ2È˻ظ´
Âé·³ÄÜÈ˰ïÎÒ·ÒëÒ»¾ä»°£¬Ð»Ð»¡£
ÒѾÓÐ6È˻ظ´
¼±£ºÂé·³»áµÂÓïµÄ´óϺ°ïæ·ÒëÏ£¬Ð»Ð»£¡
ÒѾÓÐ1È˻ظ´
Âé·³´ó¼Ò¿´ÏÂÕâ¾ä»°ÊÇʲôÒâ˼£¬Ð»Ð»ÁË£¡
ÒѾÓÐ6È˻ظ´
³ÂÁÖÁØ
ÖÁ×ðľ³æ (ÕýʽдÊÖ)
- Ó¦Öú: 45 (СѧÉú)
- ½ð±Ò: 10716.7
- ºì»¨: 4
- Ìû×Ó: 963
- ÔÚÏß: 512.1Сʱ
- ³æºÅ: 536264
- ×¢²á: 2008-03-30
- ÐÔ±ð: GG
- רҵ: Ò©Îï·ÖÎö
¡¾´ð°¸¡¿Ó¦Öú»ØÌû
|
Results BBJ inhibited CYP3A and CYP2C9 activity in vitro, with 50% inhibitory concentrations (IC50) of less than 2%, but without evidence of mechanism-based (irreversible) inhibition. Grapefruit juice (GFJ) also inhibited CYP3A activity, but inhibitory potency was increased by pre-incubation, consistent with mechanism-based inhibition. In clinical studies, GFJ significantly increased area under the plasma concentration−time curve (AUC) for the CYP3A substrate buspirone. The geometric mean ratio (GMR = AUC with GFJ divided by AUC with water) was 2.12. In contrast, the effect of BBJ (GMR = 1.39) was not significant. In the study of flurbiprofen (CYP2C9 substrate), the positive control inhibitor fluconazole significantly increased flurbiprofen AUC (GMR = 1.71), but BBJ had no significant effect (GMR = 1.03). À¶Ý®Ö¾ßÓÐÌåÍâÒÖÖÆCYP3AºÍCYP2C9µÄ»îÐÔ£¬IC50µÍÓÚ2%£¬µ«Ã»ÓÐÖ¤¾Ý±íÃ÷ËüÊÇ»úÀíÐÔÒÖÖÆ£¨²»¿ÉÄæ£©¡£ÆÏÌÑèÖÖÒàÄÜÒÖÖÆCYP3AµÄ»îÐÔ£¬µ«Ô¤·õÓýÄÜÌá¸ßÒÖÖÆÁ¦£¬·ûºÏ»úÀíÐÔÒÖÖÆ¡£ÔÚÁÙ´²Ñо¿ÖУ¬ÆÏÌÑèÖÖÏÔÖøÌá¸ßÁËCYP3AµÄµ×Îï¶¡ÂÝ»·ÍªµÄAUC,¼¸ºÎƽ¾ù±ÈÂÊ£¨GMR)Ϊ2.12¡£Ïà±È֮ϣ¬À¶Ý®ÖµÄЧ¹û²»Ã÷ÏÔ£¨GMR=1.39)¡£¶Ô·ú±ÈÂå·ÒµÄÑо¿ÖУ¨CYP2C9µÄµ×Î£¬ÑôÐÔ¶ÔÕÕ·ú¿µßò£¨CYP2C9µÄÒÖÖÆ¼Á£©ÏÔÖøÌá¸ßÁË·ú±ÈÂå·ÒµÄAUC£¨GMR=1.71)£¬µ«À¶Ý®ÖÎÞÃ÷ÏÔЧ¹û(GMR = 1.03)¡£ Conclusion The increased buspirone AUC associated with BBJ is quantitatively small and could have occurred by chance. BBJ has no effect on flurbiprofen AUC. The studies provide no evidence for concern about clinically important pharmacokinetic drug interactions of BBJ with substrate drugs metabolized by CYP3A or CYP2C9. À¶Ý®Ö¶ÔÌá¸ß¶¡ÂÝ»·ÍªµÄAUC×÷ÓÃСÇÒ¿ÉÄÜÊÇżȻ·¢Éú¡£À¶Ý®Ö¶Ô·ú±ÈÂå·ÒµÄAUCÎÞ×÷Ó᣸ÃÑо¿±íÃ÷À¶Ý®Ö¶ÔCYP3AºÍCYP2C9µÄµ×ÎïÒ©ÎïµÄÒ©¶¯Ñ§Ó°Ïì²¢²»¾ßÓÐÁÙ´²ÒâÒå¡£ |
4Â¥2013-04-12 02:11:39













»Ø¸´´ËÂ¥